What is the Study Goal? This study is looking at an investigational medicine called Pociredir to see if it is safe and if it works as expected to help people with sickle cell disease.
>
18 to 65 years
YearsSCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
1
This study seeks to understand the safety of a gene editing therapy called CRISPR_SCD001 and if this treatment can help people with severe sickle cell disease get better.
This study is being conducted by Sickle Cell 101 to understand our sickle cell and global community’s thoughts on sickle cell trait, genotype awareness, and educational gaps associated with the evolving research about potential complications of sickle cell trait.
Hemoglobin levels in people living with sickle cell disease are typically lower than the average person.
>
18
YearsSCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
2
“The Electronic Patient Reported Pain Assessment in Sickle Cell” study aims to gather insights into painful crises in people living with sickle cell disease.
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.
The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.
>
12
YearsSCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
3
